1,1-Bis(4-hydroxyphenyl)-1-phenylethane


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:26918604IVTH0.000000000001 - 0.0000001 M 0.00001 MAffects cell metabolismMetabolic endocrine-mediated perturbations
IVTH0.000000000001 - 0.0000001 M 0.00001 MCancer phenotypeEndocrine-mediated cancer
PMID:28616630IVTH0.000000000001 - 0.0001 M 0.0000005 - 0.000005 MCancer phenotypeEndocrine-mediated cancer
PMID:30077407IVR0.001 mg/kg 0.001 mg/kgAffects glucose metabolismMetabolic endocrine-mediated perturbations
IVR250 mg/kg/day 250 mg/kg/dayDecreased uterine weightsReproductive endocrine-mediated perturbations
IVR10 mg/kg/day 10 mg/kg/dayDecreased uterine weightsReproductive endocrine-mediated perturbations
IVR50 mg/kg/day 50 mg/kg/dayDecreased uterine weightsReproductive endocrine-mediated perturbations
IVR0.1 mg/kg -No significant effects observed-
PMID:31388671IVTH0.000001 M 0.000001 MAffects expression of progesterone receptor (PR)Reproductive endocrine-mediated perturbations
IVTH0.000001 M 0.000001 MCancer phenotypeEndocrine-mediated cancer

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.